Form 8-K
8-K — Viking Therapeutics, Inc.
Accession: 0001193125-26-436145
Filed: 2026-10-28
Period: 2026-10-28
CIK: 0001607678
SIC: 2834 (PHARMACEUTICAL PREPARATIONS)
Item: Results of Operations and Financial Condition
Item: Financial Statements and Exhibits
Documents
8-K — vktx-20261028.htm (Primary)
EX-99.1 (vktx-ex99_1.htm)
GRAPHIC (img201808844_0.jpg)
XML — IDEA: XBRL DOCUMENT (R1.htm)
8-K
8-K (Primary)
Filename: vktx-20261028.htm · Sequence: 1
8-K
0001607678false00016076782026-10-282026-10-28
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): October 28, 2026
Viking Therapeutics, Inc.
(Exact name of Registrant as Specified in Its Charter)
Delaware
001-37355
46-1073877
(State or Other Jurisdiction
of Incorporation)
(Commission File Number)
(IRS Employer
Identification No.)
9920 Pacific Heights Blvd, Suite 500
San Diego, California
92121
(Address of Principal Executive Offices)
(Zip Code)
Registrant’s Telephone Number, Including Area Code: 858 704-4660
N/A
(Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
Title of each class
Trading
Symbol(s)
Name of each exchange on which registered
Common Stock, par value $0.00001 per share
VKTX
The Nasdaq Stock Market LLC
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 2.02 Results of Operations and Financial Condition.
On October 28, 2026, we issued a press release reporting our financial results for the third quarter ended September 30, 2026 and providing a corporate update. The full text of the press release is furnished as exhibit 99.1 to this Current Report on Form 8-K and incorporated herein by reference.
In accordance with General Instructions B.2 of Form 8-K, the information in Item 2.02 of this Current Report on Form 8-K shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liability of that section, and shall not be incorporated by reference into any registration statement or other document filed under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such filing.
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits
Exhibit No
Description
99.1
Press release issued October 28, 2026, reporting financial results for the third quarter ended September 30, 2026 and providing a corporate update.
104
Cover Page Interactive Data File (embedded with the Inline XBRL document)
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Viking Therapeutics, Inc.
Date:
October 28, 2026
By:
/s/ Brian Lian, Ph.D.
President and Chief Executive Officer
(Principal Executive Officer)
EX-99.1
EX-99.1
Filename: vktx-ex99_1.htm · Sequence: 2
EX-99.1
Exhibit 99.1
Viking Therapeutics Reports Third Quarter 2026 Financial Results and Provides Corporate Update
-- VANQUISH Phase 3 Trials for Subcutaneous VK2735 in Obesity Continue to Advance --
-- SUNRISE Phase 3 Trials for Oral VK2735 Initiated --
-- Positive Top-Line Results Announced for VK2735 Maintenance Dosing Study; Part 2 Study Initiated --
-- Phase 1 SAD Study of Amylin Agonist VK3019 Nearing Completion --
-- Strong Quarter-End Cash Position of $960 Million --
Conference call scheduled for 4:30 p.m. ET today
SAN DIEGO, October 28, 2026 -- Viking Therapeutics, Inc. (Viking) (Nasdaq: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced its financial results for the third quarter and nine months ended September 30, 2026, and provided an update on its clinical pipeline and other corporate developments.
Highlights from the Third Quarter Ended September 30, 2026, and Other Recent Events:
“During the third quarter, Viking continued to advance and expand development activities in its obesity franchise. We recently announced the initiation of the SUNRISE Phase 3 program with the oral tablet formulation of VK2735, representing the third and fourth registration trials to be underway. The SUNRISE oral Phase 3 program will closely mirror the ongoing VANQUISH Phase 3 program evaluating the subcutaneous formulation and we are excited to have these important clinical trials underway. In the third quarter we also announced positive results from our initial VK2735 dose-ranging maintenance study. These results demonstrated an impressive maintenance effect, excellent tolerability, and serve to further establish VK2735 as a differentiated potential treatment option for patients with obesity. Following the successful initial readout, we announced another milestone with the initiation of Part 2 of the maintenance study. As with Part 1, subjects will transition from a weekly induction period to a range of VK2735 maintenance options
including daily oral doses, every-other-week subcutaneous doses, monthly subcutaneous doses, or placebo. The potential availability of both a tablet and a subcutaneous formulation, across a variety of dosing regimens, will offer unmatched optionality and flexibility to best support a personalized and sustainable weight loss journey. Also, during the quarter, the Phase 1 study of our dual amylin and calcitonin receptor agonist VK3019 continued to advance. Upon completion, we expect to initiate a 28-day multiple ascending dose study of VK3019 in the first quarter of 2027. To support our robust pipeline, as well as the activities related to the potential commercial launch of VK2735, during the quarter the company successfully closed concurrent upsized public offerings of common stock and convertible senior notes, resulting in a strong quarter-end cash balance of $960 million. This provides the company with the runway to execute multiple Phase 3 trials and build the infrastructure to execute a strong and effective commercial strategy.”
Pipeline and Recent Corporate Highlights
•
Phase 3 VANQUISH 1 & 2 Trials for Subcutaneous VK2735 in Obesity Continue to Advance. VK2735 is a wholly owned long-acting dual agonist of the glucagon like peptide-1, or GLP-1 receptor, and the glucose dependent insulinotropic polypeptide, or GIP receptor, in development for the potential treatment of obesity and other metabolic disorders. Top-line data from the company’s prior Phase 2 VENTURE study of VK2735 in adults with obesity demonstrated statistically significant reductions in mean body weight from baseline, ranging up to 14.7% after 13 weekly doses, with no signs of plateau. The VENTURE study also showed VK2735 to be safe and well tolerated through 13 weeks of dosing, with the majority of treatment emergent adverse events characterized as mild or moderate, and resolving quickly.
Based on the positive findings from the Phase 2 VENTURE study, and subsequent feedback from the U.S. Food and Drug Administration (FDA), the company advanced the subcutaneous formulation of VK2735 into Phase 3 development, initiating the VANQUISH Phase 3 registration program in June of last year. The VANQUISH program consists of two clinical trials: VANQUISH-1 in adults with obesity and VANQUISH-2 in adults with obesity and type 2 diabetes. Each study is a randomized, double-blind, placebo-controlled, multicenter trial designed to assess the efficacy and safety of VK2735 administered by subcutaneous injection once weekly for 78 weeks.
The VANQUISH-1 study enrolled approximately 4,500 patients within approximately five months of initiation. The VANQUISH-2 study enrolled approximately 1,000 patients within approximately 9 months of initiation. Participants in each trial have been randomized to weekly doses of 7.5 mg, 12.5 mg, 17.5 mg, or placebo.
The primary endpoint of the VANQUISH trials is the percent change in body weight from baseline for participants receiving VK2735 as compared to placebo after 78 weeks of treatment. Secondary and exploratory endpoints will evaluate a range of additional safety and efficacy measures, including the percentage of patients who achieve at least 5%, 10%, 15% and 20% weight loss. Each study will include an extension portion allowing participants the opportunity to continue receiving treatment following completion of the primary dosing period, including patients who were randomized to placebo for the initial 78-week treatment period.
During the third quarter, both VANQUISH studies continued to advance on track. The company expects these studies to be completed in 2027.
•
VANQUISH Extension Studies to Commence in 1Q27. Following completion of the 78-week treatment period in both VANQUISH studies, participants are eligible to enroll in extension studies, enabling them to continue their treatment for up to an additional 52 weeks. The extension studies will provide important long-term safety and efficacy data and afford subjects the opportunity to continue receiving VK2735 upon completion of the primary dosing periods. In addition, the VANQUISH-1 extension study will include certain less-frequent dosing regimens, including every-other-week and monthly administration. The company anticipates the results of the extension studies to be available in 2028.
•
SUNRISE Oral Phase 3 VK2735 Program Initiated; SUNRISE 1 & 2 Trials Underway. In addition to its subcutaneous formulation, Viking is also advancing an oral tablet formulation of VK2735. If successful, the tablet formulation is positioned to become the first oral dual GLP-1/GIP agonist to reach the market. The company believes the availability of both oral and injectable formulations is a key differentiating feature of VK2735, as no other dual or triple agonist is currently available in both formulations. Importantly, using the same active ingredient across formulations may increase treatment adherence by reducing the risk of unexpected side effects compared with switching between therapies that do not share the same active agent. Viking believes the availability of both a tablet and a subcutaneous formulation will offer much needed optionality, flexibility and convenience to best support a personalized and sustainable weight loss journey - from the induction phase of weight loss through long-term weight management.
As with the company’s subcutaneous studies to date, the Phase 1 and Phase 2 trials of Viking’s oral tablet formulation of VK2735 successfully achieved their primary and secondary objectives. The Phase 2 VENTURE Oral Dosing study of VK2735 evaluated once daily doses of the tablet formulation. Top-line results demonstrated statistically significant reductions in mean body weight after 13 weeks, ranging up to 12.2% from baseline. Up to 80% of subjects in VK2735 treatment groups achieved at least 10% weight loss after 13 weeks, compared with only 5% of placebo treated subjects. The tablet formulation also demonstrated encouraging safety and tolerability through 13 weeks of daily dosing. The vast majority of drug-related treatment-emergent adverse events were characterized as mild or moderate, with no meaningful difference in gastrointestinal (GI)-related adverse events between subjects treated with VK2735 and placebo.
Earlier this month, the company announced the initiation of the SUNRISE Phase 3 registration program evaluating oral VK2735. The SUNRISE program includes two studies: SUNRISE-1 in adults with obesity and SUNRISE-2 in obese or overweight adults with type 2 diabetes. Each study is a randomized, double-blind, placebo-controlled, multicenter trial designed to assess the efficacy and safety of oral VK2735, with patients receiving once-daily doses for 68 weeks. SUNRISE-1 and SUNRISE-2 are each targeting enrollment of 560 adults. Participants in each trial will be randomized to one of four treatment groups receiving once-daily VK2735 doses of 27.5 mg, 35 mg, 55 mg, or placebo.
Viking is very pleased to have these important trials underway, as it believes oral VK2735 may represent another differentiated and high value treatment option for patients and physicians alike.
•
Positive Top-Line Results Announced for Part 1 of VK2735 Maintenance Dosing Study. Based on VK2735's promising efficacy and differentiated pharmacokinetic (PK) profile, the company is evaluating a range of novel dosing regimens for both the induction and the long-term maintenance of weight loss. Providing flexible options for long-term therapy, including lower dosing and less frequent administration, may improve treatment persistence following achievement of individual weight loss goals. In addition, affording patients the option to remain on the same therapeutic compound, in either a tablet or an injectable form, throughout their treatment journey may reduce the potential for undesired side effects compared with options that involve switching between different therapeutic agents. The company believes this may also lead to improved adherence to therapy and increase the probability of realizing the long-term benefits of weight loss such as reduced cardiovascular risks, improved physical function and enhanced quality of life.
In the third quarter the company reported positive results from Part 1 of a two-part range-finding study. This study, which was designed to explore a variety of maintenance dosing regimens, demonstrated VK2735’s ability not only to achieve significant weight loss during the induction phase, but to also maintain a high percentage of the initial weight loss long-term using lower and less frequent dosing regimens.
Part 1 of the maintenance study was focused on subcutaneous dosing. The novel design incorporated multiple parts – a 21-week induction period, a 12-week maintenance period evaluating monthly or every-other-week dosing, and a 33-week dosing period utilizing a 17.5 mg weekly dose. A total of 180 subjects were randomized across 11 treatment groups. Subjects were required to have a BMI ≥30 kg/m2 but no other comorbidities. Induction doses ranged from 15.0 mg to 22.5 mg per week, or placebo, administered once weekly by subcutaneous injection for 21 weeks. Following the 21-week induction period, subjects were transitioned to a range of subcutaneous maintenance regimens, or placebo, for an additional 12 weeks.
Through the initial 21 weeks of weekly dosing, robust weight loss was observed at all dose levels, with no signs of plateau. Week 21 weight loss ranged from approximately 16% to approximately 19% compared with approximately 0% for placebo. All doses clearly separated from placebo starting at Week 4, with p-values at each dosing level less than 0.0001 compared with placebo. Among treated subjects, 98% achieved 5% weight loss, 90% achieved 10%, 65% achieved 15%, and 32% achieved 20% weight loss. This compares well with the placebo cohort, for which only 13% achieved 5% weight loss and none achieved 10%, 15% or 20% weight loss at Week 21. Based on the weight loss trajectories among VK2735-treated subjects at Week 21, the company believes that further weight loss is likely to be observed with continued dosing.
Following the 21-week induction phase of the study, subjects were transitioned from weekly dosing to every-other-week or monthly dosing for an additional 12 weeks. Among subjects dosed every-other-week, mean weight loss retained at Week 33 ranged from 83% to 97%, compared with 61% among subjects transitioned from 17.5 mg weekly to placebo, with p-values less than 0.01 for each cohort vs. placebo. Among subjects transitioned to monthly dosing, mean weight loss retained at Week 33 ranged from 82% to 90%, compared with 61% for placebo, with p-values less than 0.01 for each cohort vs. placebo. The significant reduction in weight rebound compared with placebo under either regimen demonstrated a compelling maintenance signal, supporting the concept of less frequent dosing as a potentially viable regimen for long-term weight management.
The maintenance study also incorporated an exploratory cohort where subjects were maintained on a 17.5 mg weekly dose for the entire 33-week treatment window. These participants demonstrated continued weight loss throughout the 33 week study period, reaching approximately 22% from baseline. No plateau was observed, suggesting further weight loss might be expected with continued dosing.
This study also demonstrated a favorable tolerability profile and low rate of discontinuations. During the 21 week induction period, common GI adverse events such as nausea, vomiting, diarrhea, and constipation were consistent with those observed in the company’s prior Phase 2 VENTURE study. This is of particular interest as these subjects were titrated faster (every two weeks) compared with the slower titration schedule (every three weeks) used in the VENTURE study.
During the maintenance period of this study, following the transition to every-other-week or monthly dosing, an encouraging tolerability profile was also observed. Treatment emergent adverse events were similar to placebo, and GI-related adverse events were low and generally no different from placebo. These data suggest that despite a gap of up to four weeks between doses, these participants did not resensitize to GI adverse events such as nausea or vomiting. This supports the company’s view that VK2735’s differentiated PK profile, with an extended half-life and excellent long-term exposures, may provide for greater flexibility in dosing compared with existing options.
The company believes these results demonstrated a credible maintenance effect, a key objective of the study. Importantly, results from this study will help inform the selection of doses in the upcoming VANQUISH extension studies, expected to begin in early 2027.
•
Part 2 Maintenance Dosing Study Initiated, to Evaluate Oral and Additional Subcutaneous Regimens.
Following the successful completion of the first part of the maintenance dosing study, the company recently initiated Part 2 of this study, designed to evaluate a range of oral maintenance regimens, along with select subcutaneous maintenance doses. Part 2 of the study is a randomized, double-blind, placebo-controlled trial in approximately 195 adults with obesity (BMI ≥30 kg/m2) who are otherwise healthy. As in Part 1, all
participants will receive initial weekly subcutaneous doses of VK2735 for 21 weeks. Following Week 21, participants will transition to a range of VK2735 maintenance dosing options including daily oral doses, monthly subcutaneous doses, every-other-week subcutaneous doses, or placebo. Study objectives are to evaluate the safety, tolerability, and pharmacokinetic profile of VK2735 under these various dosing regimens. Exploratory endpoints will assess changes in body weight from baseline and from Week 21 to the end of the study at Week 33.
The company expects the results from Part 2 of this study to be available in 2027.
•
Phase 1 Single Ascending Dose Study of Amylin Agonist VK3019 Nearing Completion. VK3019 is an investigational dual amylin and calcitonin receptor agonist (DACRA) in development for the potential treatment of obesity. Preclinical data for this program showed robust effects on body weight, food intake, and metabolism in healthy rats, diet-induced obese mice, and obese primates compared to control-treated animals.
During the second quarter, the company initiated a Phase 1 single ascending dose (SAD) clinical trial evaluating VK3019. The Phase 1 trial is a randomized, double-blind, placebo-controlled SAD study in healthy adults with BMI ≥27. The primary objectives of the study include an evaluation of the safety, tolerability, and pharmacokinetics of VK3019 following administration of single subcutaneous doses. Exploratory pharmacodynamic assessments include evaluations of changes in body weight after a single-dose administration.
The company expects to complete the SAD study later this quarter and initiate a 4 week multiple ascending dose (MAD) study of VK3019 in 1Q27.
The addition of VK3019 to Viking’s clinical pipeline represents an important expansion of the company’s obesity franchise and further illustrates Viking’s commitment to treating obesity first with the goal of helping patients achieve and maintain a weight that will allow them to improve their overall health and quality of life.
•
Strong Quarter-End Cash Position of $960 Million Provides Resources to Execute Multiple Long-Term Objectives. In September, Viking successfully closed concurrent upsized public offerings of common stock and convertible senior notes, resulting in gross proceeds to the company of approximately $575.0 million. Following completion of the offering, at the end of the third quarter the company held $960 million in cash, cash equivalents and short-term investments. In addition to providing the runway needed to reach important milestones, including completion of the company’s ongoing Phase 3 obesity trials, and the development of earlier stage programs, these resources will support the company’s growing commercial operations, infrastructure and plans as it prepares for the potential commercial launch of VK2735.
•
Upcoming Scientific Conference Presentations.
Viking plans to make the following presentations at scientific conferences in the fourth quarter:
ObesityWeek; November 14 – 17, 2026 - Washington, D.C:
•
VANQUISH-2 SC VK2735 Study in Adults With Overweight and Type 2 Diabetes: Baseline Characteristics
Saturday, November 14,2026, 7:30 pm - 8:30 pm ET
Poster presentation
•
Impact of SC VK2735 on Obesity Severity and Cardiometabolic Parameters in the VENTURE Study
Sunday, November 15, 2026, 2:30 pm - 3:30 pm ET
Poster presentation
•
Upcoming Investor Events
Viking management will participate in the following upcoming investor events:
•
Stifel 2026 Healthcare Conference
New York, NY
November 10 - 12, 2026
•
Truist 2026 BioPharma Symposium
New York, NY
November 12, 2026
•
UBS Global Biopharma Conference
London, UK
November 16 - 17, 2026
•
Jefferies Global Healthcare Conference
London, UK
November 16 - 19, 2026
•
Piper Sandler 38th Annual Healthcare Conference
New York, NY
December 1 – 3, 2026
•
J.P. Morgan 2027 Healthcare Conference
San Francisco, CA
January 11 – 14, 2027
Third Quarter and Nine Months 2026 Financial Highlights
Third Quarter ended September 30, 2026, and 2025
Research and development expenses were $166.8 million for the three months ended September 30, 2026, compared to $90.0 million for the same period in 2025. The increase was primarily due to increased expenses related to planned and ongoing clinical studies, manufacturing for the company’s drug candidates, stock-based compensation, salaries and benefits and third-party consultants, partially offset by decreased expenses related to preclinical studies.
General and administrative expenses were $20.3 million for the three months ended September 30, 2026, compared to $8.6 million for the same period in 2025. The increase was primarily due to increased expenses related to legal and patent services, third-party consultants, stock-based compensation, and salaries and benefits. These increases reflect the company’s rapid overall growth compared with the same period in 2025.
For the three months ended September 30, 2026, Viking reported a net loss of $183.2 million, or $1.55 per share, compared to a net loss of $90.8 million, or $0.81 per share, in the corresponding period in 2025. The increase in net loss for the three months ended September 30, 2026, was primarily due to increased research and development expenses and general and administrative expenses, noted previously, compared to the same period in 2025.
Nine Months ended September 30, 2026, and 2025
Research and development expenses were $432.7 million for the nine months ended September 30, 2026, compared to $191.5 million for the same period in 2025. The increase was primarily due to increased expenses related to planned and ongoing clinical studies, stock-based compensation, manufacturing for the company’s drug candidates, salaries and benefits, and third-party consultants, partially offset by decreased expenses related to preclinical studies.
General and administrative expenses were $51.1 million for the nine months ended September 30, 2026, compared to $37.1 million for the same period in 2025. The increase was primarily due to increased expenses related to third-party consultants, legal and patent services, and salaries and benefits, partially offset by decreased expenses related to stock-based compensation. These increases reflect the company’s rapid overall growth compared with the same period in 2025.
For the nine months ended September 30, 2026, Viking reported a net loss of $469.5 million, or $4.03 per share, compared to a net loss of $202.0 million, or $1.80 per share, in the corresponding period in 2025. The increase in net loss for the nine months ended September 30, 2026, was primarily due to increased research and development expenses and general and administrative expenses, noted previously, compared to the same period in 2025.
Balance Sheet as of September 30, 2026
At September 30, 2026, Viking held cash, cash equivalents, and short-term investments of $960 million, compared to $706 million as of December 31, 2025. This balance includes the aggregate net proceeds of approximately $550 million from the company’s recent financing.
Conference Call
Management will host a conference call to discuss Viking's third quarter 2026 financial results today at 4:30 pm Eastern. To participate in the conference call, please dial (844) 850-0543 from the U.S. or (412) 317-5199 from outside the U.S. In addition, following the completion of the call, a telephone replay will be accessible until November 4, 2026, by dialing (855) 669-9658 from the U.S. and Canada, or (412) 317-0088 and entering conference ID # 1882451. Those interested in listening to the conference call live via the internet may do so by visiting the Webcasts page of Viking's website at https://ir.vikingtherapeutics.com/webcasts-presentations. An archive of the webcast will also be available on the Webcasts page of Viking's website for 30 days.
About Viking Therapeutics, Inc.
Viking Therapeutics, Inc. is a clinical-stage biopharmaceutical company advancing a next-generation portfolio of therapies for obesity and metabolic disease. Guided by deep expertise in metabolic biology and rigorous science, Viking is developing innovative treatments to help people achieve meaningful, lasting health improvements by treating obesity first. The company's lead program, VK2735, is a dual glucagon-like peptide 1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) receptor agonist in development in both subcutaneous and oral formulations for obesity. VK2735 is currently being evaluated in Phase 3 clinical studies for obesity, along with maintenance dosing strategies designed to support long-term weight management. Viking is also advancing additional obesity programs, including VK3019, an amylin receptor agonist, VK2809, an orally available thyroid hormone receptor beta agonist for metabolic and liver disease, and VK0214 for the rare genetic disorder X-linked adrenoleukodystrophy (X-ALD).
For more information about Viking Therapeutics, please visit www.vikingtherapeutics.com.
Forward-Looking Statements
This press release contains forward-looking statements regarding Viking Therapeutics, Inc., under the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995, including statements about Viking's expectations regarding its clinical and preclinical development programs, anticipated timing for reporting clinical data and cash resources. Forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially and adversely and reported results should not be considered as an indication of future performance. These risks and uncertainties include, but are not limited to: risks associated with the success, cost and timing of Viking's product
candidate development activities and clinical trials, including those for VK2735, VK3019, VK0214, VK2809, and the company's other incretin and other receptor agonists; risks that prior clinical and preclinical results may not be replicated; risks regarding regulatory requirements; and other risks that are described in Viking's most recent periodic reports filed with the Securities and Exchange Commission including Viking's Annual Report on Form 10-K for the year ended December 31, 2025, and subsequent Quarterly Reports on Form 10-Q, including the risk factors set forth in those filings. These forward-looking statements speak only as of the date hereof. Viking disclaims any obligation to update these forward-looking statements except as required by law.
Viking Therapeutics, Inc.
Condensed Consolidated Statements of Operations and Comprehensive Loss
(In thousands, except per share amounts)
(Unaudited)
Three Months Ended
September 30,
Nine Months Ended
September 30,
2026
2025
2026
2025
Revenues
$
—
$
—
$
—
$
—
Operating expenses:
Research and development
166,804
89,953
432,708
191,496
General and administrative
20,308
8,608
51,126
37,108
Total operating expenses
187,112
98,561
483,834
228,604
Loss from operations
(187,112
)
(98,561
)
(483,834
)
(228,604
)
Other income (expense):
Amortization of financing costs
—
(8
)
—
(56
)
Interest income, net
4,014
7,772
14,359
26,669
Interest expense, net
(88
)
—
(88
)
—
Realized gain on investments
—
10
30
14
Total other income, net
3,926
7,774
14,301
26,627
Net loss
(183,186
)
(90,787
)
(469,533
)
(201,977
)
Other comprehensive loss, net of tax:
Unrealized (loss) gain on investments
(518
)
540
(2,067
)
1,129
Foreign currency translation (loss) gain
(27
)
—
(9
)
33
Comprehensive loss
$
(183,731
)
$
(90,247
)
$
(471,609
)
$
(200,815
)
Basic and diluted net loss per share
$
(1.55
)
$
(0.81
)
$
(4.03
)
$
(1.80
)
Weighted-average shares used to compute basic
and diluted net loss per share
118,050
112,320
116,636
112,217
Viking Therapeutics, Inc.
Condensed Consolidated Balance Sheets
(In thousands, except share and per share amounts)
September 30,
2026
December 31,
2025
(Unaudited)
Assets
Current assets:
Cash and cash equivalents
$
677,609
$
165,810
Short-term investments – available-for-sale
282,204
539,929
Prepaid clinical trial and preclinical study costs
10,008
8,053
Prepaid expenses and other current assets
3,178
1,806
Total current assets
972,999
715,598
Right-of-use assets
3,853
85
Restricted cash
202
—
Deposits
113
46
Total assets
$
977,167
$
715,729
Liabilities and stockholders’ equity
Current liabilities:
Accounts payable
$
82,134
$
53,251
Other accrued liabilities
51,739
23,279
Lease liability, current
24
137
Total current liabilities
133,897
76,667
Lease liability, net of current portion
4,014
—
Convertible Notes
250,656
—
Total long-term liabilities
254,670
—
Total liabilities
388,567
76,667
Commitments and contingencies
Stockholders’ equity:
Preferred stock, $0.00001 par value: 10,000,000 shares authorized at September 30, 2026 and December 31, 2025; no shares issued and outstanding at September 30, 2026 and December 31, 2025
—
—
Common stock, $0.00001 par value: 300,000,000 shares authorized at September 30, 2026 and December 31, 2025; 127,521,229 shares issued and outstanding at September 30, 2026 and 114,793,067 shares issued and outstanding at December 31, 2025
1
1
Additional paid-in capital
1,907,376
1,486,229
Accumulated deficit
(1,317,079
)
(847,546
)
Accumulated other comprehensive (loss) gain
(1,698
)
378
Total stockholders’ equity
588,600
639,062
Total liabilities and stockholders’ equity
$
977,167
$
715,729
Contacts:
Viking Therapeutics
Greg Zante
Chief Financial Officer
858-704-4672
gzante@vikingtherapeutics.com
Vida Strategic Partners
Stephanie Diaz (Investors)
415-675-7401
sdiaz@vidasp.com
Jennifer Arcure (Media)
917-603-0681
jarcure@vidasp.com
GRAPHIC
GRAPHIC
Filename: img201808844_0.jpg · Sequence: 3
Binary file (13142 bytes)
Download img201808844_0.jpg
XML — IDEA: XBRL DOCUMENT
XML
Filename: R1.htm · Sequence: 6
v3.26.3
Document And Entity Information
Oct. 28, 2026
Cover [Abstract]
Document Type
8-K
Amendment Flag
false
Document Period End Date
Oct. 28, 2026
Entity Registrant Name
Viking Therapeutics, Inc.
Entity Central Index Key
0001607678
Entity Emerging Growth Company
false
Entity File Number
001-37355
Entity Incorporation, State or Country Code
DE
Entity Tax Identification Number
46-1073877
Entity Address, Address Line One
9920 Pacific Heights Blvd, Suite 500
Entity Address, City or Town
San Diego
Entity Address, State or Province
CA
Entity Address, Postal Zip Code
92121
City Area Code
858
Local Phone Number
704-4660
Entity Information, Former Legal or Registered Name
N/A
Written Communications
false
Soliciting Material
false
Pre-commencement Tender Offer
false
Pre-commencement Issuer Tender Offer
false
Title of 12(b) Security
Common Stock, par value $0.00001 per share
Trading Symbol
VKTX
Security Exchange Name
NASDAQ
X
- Definition
Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.
+ References
No definition available.
+ Details
Name:
dei_AmendmentFlag
Namespace Prefix:
dei_
Data Type:
xbrli:booleanItemType
Balance Type:
na
Period Type:
duration
X
- Definition
Area code of city
+ References
No definition available.
+ Details
Name:
dei_CityAreaCode
Namespace Prefix:
dei_
Data Type:
xbrli:normalizedStringItemType
Balance Type:
na
Period Type:
duration
X
- Definition
Cover page.
+ References
No definition available.
+ Details
Name:
dei_CoverAbstract
Namespace Prefix:
dei_
Data Type:
xbrli:stringItemType
Balance Type:
na
Period Type:
duration
X
- Definition
For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.
+ References
No definition available.
+ Details
Name:
dei_DocumentPeriodEndDate
Namespace Prefix:
dei_
Data Type:
xbrli:dateItemType
Balance Type:
na
Period Type:
duration
X
- Definition
The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.
+ References
No definition available.
+ Details
Name:
dei_DocumentType
Namespace Prefix:
dei_
Data Type:
dei:submissionTypeItemType
Balance Type:
na
Period Type:
duration
X
- Definition
Address Line 1 such as Attn, Building Name, Street Name
+ References
No definition available.
+ Details
Name:
dei_EntityAddressAddressLine1
Namespace Prefix:
dei_
Data Type:
xbrli:normalizedStringItemType
Balance Type:
na
Period Type:
duration
X
- Definition
Name of the City or Town
+ References
No definition available.
+ Details
Name:
dei_EntityAddressCityOrTown
Namespace Prefix:
dei_
Data Type:
xbrli:normalizedStringItemType
Balance Type:
na
Period Type:
duration
X
- Definition
Code for the postal or zip code
+ References
No definition available.
+ Details
Name:
dei_EntityAddressPostalZipCode
Namespace Prefix:
dei_
Data Type:
xbrli:normalizedStringItemType
Balance Type:
na
Period Type:
duration
X
- Definition
Name of the state or province.
+ References
No definition available.
+ Details
Name:
dei_EntityAddressStateOrProvince
Namespace Prefix:
dei_
Data Type:
dei:stateOrProvinceItemType
Balance Type:
na
Period Type:
duration
X
- Definition
A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Number 240
-Section 12
-Subsection b-2
+ Details
Name:
dei_EntityCentralIndexKey
Namespace Prefix:
dei_
Data Type:
dei:centralIndexKeyItemType
Balance Type:
na
Period Type:
duration
X
- Definition
Indicate if registrant meets the emerging growth company criteria.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Number 240
-Section 12
-Subsection b-2
+ Details
Name:
dei_EntityEmergingGrowthCompany
Namespace Prefix:
dei_
Data Type:
xbrli:booleanItemType
Balance Type:
na
Period Type:
duration
X
- Definition
Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.
+ References
No definition available.
+ Details
Name:
dei_EntityFileNumber
Namespace Prefix:
dei_
Data Type:
dei:fileNumberItemType
Balance Type:
na
Period Type:
duration
X
- Definition
Two-character EDGAR code representing the state or country of incorporation.
+ References
No definition available.
+ Details
Name:
dei_EntityIncorporationStateCountryCode
Namespace Prefix:
dei_
Data Type:
dei:edgarStateCountryItemType
Balance Type:
na
Period Type:
duration
X
- Definition
Former Legal or Registered Name of an entity
+ References
No definition available.
+ Details
Name:
dei_EntityInformationFormerLegalOrRegisteredName
Namespace Prefix:
dei_
Data Type:
xbrli:normalizedStringItemType
Balance Type:
na
Period Type:
duration
X
- Definition
The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Number 240
-Section 12
-Subsection b-2
+ Details
Name:
dei_EntityRegistrantName
Namespace Prefix:
dei_
Data Type:
xbrli:normalizedStringItemType
Balance Type:
na
Period Type:
duration
X
- Definition
The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Number 240
-Section 12
-Subsection b-2
+ Details
Name:
dei_EntityTaxIdentificationNumber
Namespace Prefix:
dei_
Data Type:
dei:employerIdItemType
Balance Type:
na
Period Type:
duration
X
- Definition
Local phone number for entity.
+ References
No definition available.
+ Details
Name:
dei_LocalPhoneNumber
Namespace Prefix:
dei_
Data Type:
xbrli:normalizedStringItemType
Balance Type:
na
Period Type:
duration
X
- Definition
Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Number 240
-Section 13e
-Subsection 4c
+ Details
Name:
dei_PreCommencementIssuerTenderOffer
Namespace Prefix:
dei_
Data Type:
xbrli:booleanItemType
Balance Type:
na
Period Type:
duration
X
- Definition
Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Number 240
-Section 14d
-Subsection 2b
+ Details
Name:
dei_PreCommencementTenderOffer
Namespace Prefix:
dei_
Data Type:
xbrli:booleanItemType
Balance Type:
na
Period Type:
duration
X
- Definition
Title of a 12(b) registered security.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Number 240
-Section 12
-Subsection b
+ Details
Name:
dei_Security12bTitle
Namespace Prefix:
dei_
Data Type:
dei:securityTitleItemType
Balance Type:
na
Period Type:
duration
X
- Definition
Name of the Exchange on which a security is registered.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Number 240
-Section 12
-Subsection d1-1
+ Details
Name:
dei_SecurityExchangeName
Namespace Prefix:
dei_
Data Type:
dei:edgarExchangeCodeItemType
Balance Type:
na
Period Type:
duration
X
- Definition
Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Number 240
-Section 14a
-Subsection 12
+ Details
Name:
dei_SolicitingMaterial
Namespace Prefix:
dei_
Data Type:
xbrli:booleanItemType
Balance Type:
na
Period Type:
duration
X
- Definition
Trading symbol of an instrument as listed on an exchange.
+ References
No definition available.
+ Details
Name:
dei_TradingSymbol
Namespace Prefix:
dei_
Data Type:
dei:tradingSymbolItemType
Balance Type:
na
Period Type:
duration
X
- Definition
Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Securities Act
-Number 230
-Section 425
+ Details
Name:
dei_WrittenCommunications
Namespace Prefix:
dei_
Data Type:
xbrli:booleanItemType
Balance Type:
na
Period Type:
duration